| Filed On | Filing |
|---|---|
| 19 Oct 2026 | Proxy statement: special meeting on November 4, 2026 |
| 14 Oct 2026 |
Form 4: Anand Bhaskar, Chief Accounting Officer
Received 100,000 shares as a grant or award |
| 06 Oct 2026 | PRE 14A |
| 29 Sep 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of September 28, 2026, by and between Summit Therapeutics Inc., a Delaware corporation (the “Company”), and AstraZeneca Holdings B.V., a Dutch private limited liability co... |
| 15 Sep 2026 |
8-K: Other Events
Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients Sustained OS Improvement Seen with Longer Follow-Up in Western Patients, Consist... |
| 14 Sep 2026 |
8-K: Other Events
1 Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study Conducted in China Ivonescimab Reduced t... |
| 03 Sep 2026 | 8-K: Other Events |
| 26 Aug 2026 | 8-K: Other Events |
| 05 Aug 2026 | 8-K: Other Events |
| 23 Jul 2026 | 424B5 |
| 23 Jul 2026 | 8-K: Entry into a Material Definitive Agreement |
| 23 Jul 2026 | 10-Q |
| 23 Jul 2026 | 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure |
| 22 Jul 2026 | 8-K: Other Events |
| 12 Jun 2026 |
Form 4: Zanganeh Mahkam, Director
Bought 3,810,000 shares ($50M) |
| 12 Jun 2026 |
Form 4: Duggan Robert W, Director
Bought 3,810,000 shares ($50M) |
| 12 Jun 2026 | 8-K: Submission of Matters to a Vote of Security Holders |
| 11 Jun 2026 | 8-K: Regulation FD Disclosure |
| 10 Jun 2026 | 424B5 |
| 09 Jun 2026 | S-3ASR |
Loading...
